Diabetes

NEW YORK — A test commonly used to identify patients with diabetes or those at risk of developing the condition may not produce accurate results among children, according to a new study conducted by researchers at the University of Michigan.

The study, published online ahead of print in the journal Diabetes Care, tested 254 overweight children using both fasting and nonfasting methods. Researchers found that the recommended test, hemoglobin A1C (HbA1C), missed more cases of prediabetes or diabetes, compared with other tests.

SIOUX FALLS, S.D. — PharmaCline has launched a topical antibiotic for prediabetes and diabetes patients that is designed to treat minor cuts, scrapes and burns.

Diabecline, the company said, is an over-the-counter antibiotic that targets the source of infection through site-specific penetration technology.

"Our Diabecline antibiotic allows users who are at greater risk of developing serious infections to achieve better care," PharmaCline CEO Steve Keough said.

CAMBRIDGE, Mass. — An online data sharing platform announced it will debut a daily blood-glucose monitoring feature for its more than 2,000 diabetes patients.

PatientsLikeMe said patients will be able to report daily glucose levels, as well as continue sharing and learning from HbA1C scores, treatments and dosages, in addition to symptoms and severity.

The feature will be launched in early December, PatientsLikeMe said.

MINNEAPOLIS — The Food and Drug Administration has approved a professional glucose monitoring system made by Medtronic, the company said.

COLUMBIA, Mo. — A new tool developed by researchers at the University of Missouri improved both the efficiency and accuracy of acquiring data needed for high-quality diabetes care, according to a new study.

WHAT IT MEANS AND WHY IT'S IMPORTANT — If there are 366 million diabetics worldwide, that means that the U.S. piece of that sugar-free pie is 7.1%. And if the U.S. diabetes population grows by more than 50.8% over the next two decades, as the International Diabetes Foundation attests, that'll mean there will be 38.6 million diabetics in this country by 2030. That's a lot of diabetes education that needs to happen between now and then, and what better place to have that happen than at the neighborhood drug store?

PRINCETON, N.J. — Bristol-Myers Squibb and AstraZeneca presented an analysis Wednesday of 14 clinical trials at the American Heart Association's Scientific Sessions in Orlando, Fla., the companies said.

The phase-2b and phase-3 trials all involved the investigational Type 2 diabetes drug dapagliflozin and, the companies said, showed that use of the drug did not lead to an unacceptable risk to adult patients' cardiovascular health compared with other treatments.

LONDON — GlaxoSmithKline announced the results from the first of eight phase-3 clinical trials that examined the efficacy of albiglutide in the treatment of Type 2 diabetes.

The Harmony 7 trial was a 32-week, head-to-head, open-label, noninferiority study that compared albiglutide, an investigational once weekly glucagon-like peptide-1 agonist, with once-daily liraglutide. According to the results, patients administered GSK's drug saw a 0.78% reduction in HbA1C, while patients administered liraglutide saw a 0.99% reduction in HbA1C.